Daehan New Pharm Co. Ltd (054670) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Daehan New Pharm Co. Ltd KRW 16,260, price KRW 5,420, upside +200.0%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Daehan New Pharm Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 5,090 KRW – 12,911 KRW · fair‑value band 12,195 KRW – 20,325 KRW · the 5,420 KRW price screens below the 16,260 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Daehan New Pharm Co. in your weekly email
Every Wednesday you see whether Daehan New Pharm Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally.
Show more
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products. The company also provides animal health and nutrition products; health supplements; and aesthetic/medical devices. The company was formerly known as Daehan New Pharm Co., Ltd and changed its name to Daehan Nupharm Co.,Ltd. in March 2025. Daehan Nupharm Co.,Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
Daehan New Pharm Co. Ltd (054670) currently trades at 5,420 KRW, while our model-based Fair Value estimate is 16,260 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 20,515 KRW per share, and 12 of the 14 models we run sit above the 5,420 KRW price.
Bear case: the Economic Profit group reads lowest at 3,584 KRW, and 2 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 12,195 KRW (bear) to 20,325 KRW (bull), the price of 5,420 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Daehan New Pharm Co. Ltd reported revenue of 202B KRW in FY2025 versus 167B KRW in FY2021, a compound +5.0%/yr. Reported net income was 15.3B KRW in FY2025, compounding −0.7%/yr from FY2021.
Key figures
Market cap 76.1B KRW (≈ $55.9M) · P/S ratio 0.37 · Dividend yield 1.8% · Net margin 7.5% · Return on equity 11.9% · Return on assets (EBIT) 12.2% · Operating margin 5.7% · Revenue (TTM) 205B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 200%, 054670 screens cheaper than that median.
Fair Value models
Bear 12,195 KRWFair Value 16,260 KRWBull 20,325 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic). Over 10 years: +8.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.3%
Dividend (yield on the price)1.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 6%
Compare Daehan New Pharm Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside+200% · Top 25%
Profitability
Return on equity (TTM)12% · Above median
Return on assets3% · Below median
Net margin (TTM)8% · Above median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth6% · Above median
Dividend yield (TTM)1.8% · Above median
Balance sheet
Debt / equity0.39× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daehan New Pharm Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/054670
Frequently asked questions
Is Daehan New Pharm Co. Ltd (054670) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 16,260 KRW versus a price of 5,420 KRW, about +200% upside (undervalued).
What is the fair value of 054670?
Our model-based fair value for Daehan New Pharm Co. Ltd is 16,260 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,420 KRW.
What is the quality score of 054670?
Daehan New Pharm Co. Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daehan New Pharm Co. Ltd (054670)?
Our model-based price target is the fair value of 16,260 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 12,195 KRW, optimistic scenario 20,325 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daehan New Pharm Co. Ltd stock forecast for 2026?
Our models put fair value at 16,260 KRW, about +200% upside versus a price of 5,420 KRW (undervalued). Cautious scenario 12,195 KRW, optimistic scenario 20,325 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daehan New Pharm Co. Ltd (054670)?
Daehan New Pharm Co. Ltd reported trailing-twelve-month revenue of about 205B KRW (latest available figure, as of Sep 24, 2026).
Does Daehan New Pharm Co. Ltd pay a dividend?
Daehan New Pharm Co. Ltd currently shows a dividend yield of about 1.85% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Daehan New Pharm Co. Ltd (054670)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daehan New Pharm Co. Ltd it is 16,260 KRW per share (as of Sep 24, 2026), against a price of 5,420 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Daehan New Pharm Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 054670 trades below its calculated fair value: price 5,420 KRW, fair value 16,260 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 054670?
No. The price is what the market pays today (5,420 KRW); the fair value is what the company's own numbers justify (16,260 KRW). For Daehan New Pharm Co. Ltd the two are 10,840 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daehan New Pharm Co. Ltd worth?
The market values Daehan New Pharm Co. Ltd at about 76.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,420 KRW; our models calculate a fair value of 16,260 KRW per share.
What do the bullish and bearish scenarios say about 054670?
Our models span a range for Daehan New Pharm Co. Ltd: cautious scenario 12,195 KRW, base 16,260 KRW, optimistic 20,325 KRW per share (as of Sep 24, 2026, price 5,420 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Daehan New Pharm Co. Ltd (054670)?
Balance-sheet figures for Daehan New Pharm Co. Ltd (as of Sep 24, 2026): return on equity 11.9%, debt of 0.39 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 054670 from its 52-week high?
Daehan New Pharm Co. Ltd trades at 5,420 KRW, about 28% below its 52-week high of 7,510 KRW and 6% above the low of 5,090 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 16,260 KRW is for.
Which stocks are comparable to Daehan New Pharm Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daehan New Pharm Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 5,420 KRW, calculated fair value 16,260 KRW (+200%), Quality Score 36/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 054670 calculated?
We run Daehan New Pharm Co. Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 16,260 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Daehan New Pharm Co. Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daehan New Pharm Co. Ltd (054670)?
The closing price on Sep 23, 2026 was 5,420 KRW. Our model-based fair value is 16,260 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daehan New Pharm Co. Ltd right now?
The large discount to fair value meets weak quality (36/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (12,195 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Daehan New Pharm Co. Ltd
How large is the market capitalisation of Daehan New Pharm Co. Ltd (054670)?
The market capitalisation of Daehan New Pharm Co. Ltd is 76.1B KRW (≈ $55.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daehan New Pharm Co. Ltd (054670)?
The price-to-sales ratio of Daehan New Pharm Co. Ltd is 0.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Daehan New Pharm Co. Ltd (054670)?
The dividend yield of Daehan New Pharm Co. Ltd is 1.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daehan New Pharm Co. Ltd (054670)?
The net margin of Daehan New Pharm Co. Ltd is 7.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daehan New Pharm Co. Ltd (054670)?
The return on equity (ROE) of Daehan New Pharm Co. Ltd is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daehan New Pharm Co. Ltd (054670)?
On an EBIT basis the return on assets of Daehan New Pharm Co. Ltd is 12.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daehan New Pharm Co. Ltd (054670)?
The operating margin of Daehan New Pharm Co. Ltd is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daehan New Pharm Co. Ltd (054670)?
Revenue at Daehan New Pharm Co. Ltd is growing +5.8% versus a year earlier (3y avg +0.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daehan New Pharm Co. Ltd (054670)?
Earnings per share at Daehan New Pharm Co. Ltd are growing +16.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daehan New Pharm Co. Ltd (054670) generate?
The free cash flow of Daehan New Pharm Co. Ltd is −46.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daehan New Pharm Co. Ltd (054670) carry?
The net debt of Daehan New Pharm Co. Ltd is 78.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daehan New Pharm Co. Ltd in the live analysis
One click puts Daehan New Pharm Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
